BAP1 is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain BAP1 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain BAP1 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [4].

BAP1 is an inclusion criterion in 2 clinical trials for malignant mesothelioma, of which 1 is open and 1 is closed. Of the trials that contain BAP1 status and malignant mesothelioma as inclusion criteria, 2 are phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BAP1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for malignant soft tissue neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and malignant soft tissue neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and pleural mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BAP1 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].